Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Lebbé, Celeste, Dutriaux, Caroline, Lesimple, Thierry, Kruit, Willem, Kerger, Joseph, Thomas, Luc, Guillot, Bernard, de Braud, Filippo, Garbe, Claus, Grob, Jean-Jacques, Loquai, Carmen, Ferraresi, Virginia, Robert, Caroline, Vasey, Paul, Conry, Robert, Isaacs, Richard, Espinosa, Enrique, Schueler, Armin, Massimini, Giorgio, Dréno, Brigitte
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7408351/
https://ncbi.nlm.nih.gov/pubmed/32610581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071727
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller